These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17061395)

  • 21. Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice.
    Fefer A
    Cancer Res; 1969 Dec; 29(12):2177-83. PubMed ID: 5369675
    [No Abstract]   [Full Text] [Related]  

  • 22. Antigenic specificities of the cellular immune response of C57BL/6 mice to the Moloney leukemia/sarcoma virus complex.
    Enjuanes L; Lee JC; Ihle JN
    J Immunol; 1979 Feb; 122(2):665-74. PubMed ID: 84033
    [No Abstract]   [Full Text] [Related]  

  • 23. Role of accessory cells in the induction of a secondary cytotoxic response to Moloney murine sarcoma virus-induced tumors.
    Biasi G; Saggin L; Dazzi F; De Rossi A; Collavo D
    J Immunol; 1983 Mar; 130(3):1447-50. PubMed ID: 6185589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Augmented immunogenicity of tumor cell membranes produced by infection with influenza virus as compared to Moloney sarcoma virus.
    Takeichi N; Austin FC; Oikawa T; Boone CW
    Cancer Res; 1978 Dec; 38(12):4580-4. PubMed ID: 214226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of Moloney murine sarcoma virus tolerance in adult mice by anti-CD4 monoclonal antibody treatment.
    Biasi G; Mazzocchi M; Facchinetti A; Panozzo M; Zanovello P; Collavo D; Chieco-Bianchi L
    Cancer Res; 1990 Sep; 50(17 Suppl):5703S-5706S. PubMed ID: 2167167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Humoral reactions in BALC/c mice with sarcomatous Moloney-induced tumor].
    Yakimenko LV; Vetrova EP; Kaminskaya LP; Berdova AG; Umansky YA
    Vopr Onkol; 1979; 25(9):46-50. PubMed ID: 573520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of amphetamine on the development of Moloney sarcoma virus-induced tumors in mice.
    Freire-Garabal M; Nuñez-Iglesias MJ; Rey-Méndez M; Pereiro-Raposo MD; Riveiro P; Fernández-Rial JC; Losada C; Gandoy M; Mayán JM
    Oncol Rep; 1998; 5(2):381-3. PubMed ID: 9468562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of effective immunity to Moloney murine sarcoma virus using monoclonal anti-idiotypic antibody as immunogen.
    Powell TJ; Spann R; Nguyenduc M; Lamon EW
    J Immunol; 1989 Feb; 142(4):1318-24. PubMed ID: 2536772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flow-microfluorometric monitoring of oligoclonal CD8+ T cell responses to an immunodominant Moloney leukemia virus-encoded epitope in vivo.
    Brawand P; Biasi G; Horvath C; Cerottini JC; MacDonald HR
    J Immunol; 1998 Feb; 160(4):1659-65. PubMed ID: 9469422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement of normal lymphocyte cytotoxicity by sera with high antibody titers against H-2 or virus-associated antigens.
    Harada M; Pearson G; Pettigrew H; Redmon L; Orr T
    Cancer Res; 1973 Nov; 33(11):2886-93. PubMed ID: 4583975
    [No Abstract]   [Full Text] [Related]  

  • 31. Detection of cellular immunity to murine sarcoma virus-induced tumors by leukocyte adherence inhibition.
    Mortensen RF
    J Natl Cancer Inst; 1979 Jan; 62(1):157-63. PubMed ID: 214608
    [No Abstract]   [Full Text] [Related]  

  • 32. Protection by immune spleen cells against challenge with Moloney sarcoma virus. Effect of stage of donor response.
    Pollack S; Nelson K
    Transplantation; 1973 May; 15(5):510-3. PubMed ID: 4710486
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunological and pathological manifestations of murine sarcoma virus (Moloney) infections.
    Schlom J; Moloney JB; Groupé V
    Cancer Res; 1970 Dec; 30(12):2955-61. PubMed ID: 5494580
    [No Abstract]   [Full Text] [Related]  

  • 34. Selective lysis of activated cells in oncorna virus infection.
    Biasi G; Facchinetti A; Mezzalira S; MacDonald HR
    Scand J Immunol; 1997 Apr; 45(4):366-70. PubMed ID: 9105423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone.
    Cerundolo V; Lahaye T; Horvath C; Zanovello P; Collavo D; Engers HD
    Eur J Immunol; 1987 Feb; 17(2):173-8. PubMed ID: 3030766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area.
    Rosato A; Zambon A; Macino B; Mandruzzato S; Bronte V; Milan G; Zanovello P; Collavo D
    Int J Cancer; 1996 Mar; 65(6):847-51. PubMed ID: 8631602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on Murine Sarcoma Virus: antigenic characterization of Murine Sarcoma Virus induced tumor cells.
    Chuat JC; Berman L; Gunvén P; Klein E
    Int J Cancer; 1969 Jul; 4(4):465-79. PubMed ID: 4899685
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-tumor immunity generated by tumor cells engineered to express B7-1 via retroviral or adenoviral gene transfer.
    Felzmann T; Ramsey WJ; Blaese RM
    Cancer Lett; 1999 Jan; 135(1):1-10. PubMed ID: 10077215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of adhesion molecules in the immune reaction to M-MSV-induced tumors.
    Rosato A; Bronte V; Mandruzzato S; Zambon A; Calderazzo F; Biasi G; Zanovello P; Collavo D
    Int J Cancer Suppl; 1992; 7():24-7. PubMed ID: 1385341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody response to Moloney type C virus-induced tumours.
    Hogg N; Wallace D; Smart JE
    Nature; 1980 Jan; 283(5744):304-6. PubMed ID: 6243399
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.